• Provides the wound with an optimal, natural healing environment.
• Can be easily prepared at the patient’s point-of-care in 5 minutes.
• Requires no capital equipment
• Created from the patient's blood, assuring safe and effective management of the wound
• Approved 20 applications with superior coverage via NCD 270.3 & code G0465.
• Medicare Advantage patients are covered via NCD 270.3.
• For patients who have exhausted their CTP applications, ActiGraft provides an option for continued advance therapy.
• Patients with exposed bone & tendon are not excluded from the NCD coverage.
• ActiGraft can be applied on large and irregular wounds up to 56 cm2, offering excellent versatility
• Inclusive treatment solution for culturally and religiously sensitive patients—no bovine, porcine, placental, or any other third party products.

ActiGraft System is intended to be used at point-of-care for the safe and rapid preparation of whole blood clot (WBC) from a small sample of a patient's own peripheral blood. Under the supervision of a healthcare professional, the WBC produced by the ActiGraft is topically applied for the management of exuding cutaneous wounds, such as leg ulcers, pressure ulcers, diabetic ulcers, and mechanically or surgically-debrided wounds.

ActiGraft is contraindicated in patients with wounds due to malignancy or wounds with active clinically diagnosed infection.

Federal Law (U.S.A.) restricts this device to sale by or on the order of a physician. Throughout the
processing and application of ActiGraft, use universal precautions as defined by the facility policy and procedure manual. All parts of the procedure shall be performed in such a manner as to minimize splashing, spattering and generation of potential droplets.

ActiGraft was not verified to be in compliance with other wound care products. Assure the patient monthly ActiGraft blood draw is below 250ml per month. The ActiGraft kit includes blood-contacting components that have been sterilized by ethylene oxide, which may cause serious allergic reactions in patients that are sensitized. Failure to follow instructions may lead to suboptimal outcomes or product failure. Outcomes may vary.

Store in the original container at a controlled room temperature of 5°C–30°C (41°F–86°F). Protect from freezing and avoid excessive heat.